Table 2.
2023 | 2024 | 2025 | 2026 | 2027 | TOTAL | |
---|---|---|---|---|---|---|
Population age 65+1 | 782,326 | 802,709 | 823,623 | 867,100 | 887,896 | 4,163,654 |
Projected hip fractures2 | 3,056 | 3,135 | 3,217 | 3,387 | 3,468 | 16,262 |
€ intervention3 | 222,808 | 228,613 | 234,570 | 246,952 | 252,875 | 1,185,819 |
Functional Decline: Projected hip fractures NOT returned to baseline functionality | ||||||
# Pre FCB4 | 1,803 | 1,850 | 1,898 | 1,998 | 2,046 | 9,595 |
# Post FCB5 | 1,253 | 1,285 | 1,319 | 1,389 | 1,422 | 6,667 |
# avoided | 550 | 564 | 579 | 610 | 624 | 2,927 |
€ Avoided 6 | 676,857 | 694,492 | 712,587 | 750,202 | 768,195 | 3,602,333 |
Net Effect (€)7 | 454,049 | 465,879 | 478,017 | 503,250 | 515,320 | 2,416,515 |
Scenario with moderate net migration increase[32].
Cost per patient estimated in Scenario analysis 2 (€72.61) applied to hip fractures estimates.
Share of hip fractures returning (41%) and not returning (59%) to baseline functionality without FCB[12].
Share of hip fractures returning (59%) and not returning (41%) to baseline functionality with FCB[12].
Annual cost of functional decline per patient equal to €1,230.65 (calculated from Bash & Kerr[36].
Derived as cost avoided minus cost of intervention.